CDR609 / CDR-Life - LARVOL DELTA

CDR609: A First-in-Class LGR5-targeted T Cell Engager for treatment of Colorectal Cancer and other solid tumors (AACR-NCI-EORTC 2025) - P1 | "CDR609 is a first-in-class T cell engager (TCE) for the treatment of LGR5-expressing solid tumors, based on the same M-gager® format as CDR404 (Phase I, NCT06402201). CDR609 also shows high specificity for LGR5, and an overall safe profile in the presence of normal human cells. Future studies will include in vivo efficacy testing and a broader range of cellular assays using ex vivo patient-derived tissues and cultured cells as part of the preclinical studies that will be included in the IND application."

IO biomarker • Colorectal Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor • CD69 • CD8 • GZMB • IFNG • IL2RA • LGR5

…CDR-Life is also presenting a poster on CDR609, the company’s newest T cell engager clinical candidate that targets LGR5, a highly cancer-specific cell surface antigen widely expressed on common solid tumors (Businesswire) - "The data presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics...."

Preclinical • Colorectal Cancer

CDR-Life Announces CDR609 as New T-Cell Engager Clinical Candidate Targeting LGR5, a Highly Cancer-specific Surface Antigen Widely Expressed on Common Solid Tumor (Businesswire) - "CDR-Life...announced CDR609 as its next clinical candidate. CDR609 is a novel TCE targeting LGR5, a surface antigen that presents a compelling opportunity for broad, tumor-specific therapeutic intervention in solid tumors....The company plans to initiate IND-enabling studies in the second half of 2025."

IND • Pipeline update • Solid Tumor